<SEC-DOCUMENT>0001213900-25-094905.txt : 20251002
<SEC-HEADER>0001213900-25-094905.hdr.sgml : 20251002
<ACCEPTANCE-DATETIME>20251001205919
ACCESSION NUMBER:		0001213900-25-094905
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20251002
FILED AS OF DATE:		20251002
DATE AS OF CHANGE:		20251001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		251366397

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0259861-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of October 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
two announcements (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on October 2, 2025 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%">- &nbsp;</TD>
    <TD STYLE="width: 88%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>Letter to shareholders</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 273pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea025986101ex99-1_immuron.htm">Letter to shareholders</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 2, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea025986101ex99-1_immuron.htm
<DESCRIPTION>LETTER TO SHAREHOLDERS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">October 2, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ASX/Nasdaq Announcement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Letter to Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Highlights:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>US Tariffs: Immuron does not anticipate any
material impact from the recently announced US tariffs on pharmaceutical products</B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Travelan<SUP><SUP><SUP>&reg;</SUP></SUP></SUP>
                                            Clinical Study: Topline results from the Travelan<SUP><SUP>&reg;</SUP></SUP> clinical study conducted by Uniformed
                                            Services University are anticipated in October 2025 </B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IMM-529 Regulatory Milestone: Immuron plans
to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October
2025</B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ProIBS<SUP><SUP>&reg;</SUP></SUP> Commercial Launch: The Australian
Launch of ProIBS<SUP><SUP>&reg;</SUP></SUP> is on track for Q4 of calendar year 2025 </B></FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IMM-986 Pre-Clinical Progress: Initial pre-clinical
research studies for IMM-986, targeting Vancomycin-resistant <I>Enterococci</I> (VRE), are anticipated to be completed by year-end 2025</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Shareholder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I am pleased to provide you with a brief update
on progress with a number of projects at Immuron Limited (ASX: IMC; NASDAQ: IMRN).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As announced on July 17, Immuron achieved
record sales up to Financial Year ending June 30, 2025. Immuron is on track to exceed FY24 first quarter sales. First quarter FY25
sales will be reported in <B>mid-October</B>. Please note that Travelan<SUP><SUP>&reg;</SUP></SUP> is imported into the United States from Australia as a
dietary supplement. It is not a pharmaceutical product and is not anticipated to be impacted by announcements regarding tariffs on
pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Clinical Trial Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron has three therapeutic products under development:
IMM-124E (Travelan<SUP><SUP>&reg;</SUP></SUP>) for traveler&rsquo;s diarrhea; IMM-529 for Clostridioides difficile infection and IMM-986 for Vancomycin-resistant
enterococci.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I<B>MM-124E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron reported on May 30 that we anticipated
the final visit of the Last Patient for the Uniformed Services University Travelan<SUP><SUP>&reg;</SUP></SUP> field study would be in July 2025 with topline
results to follow in October 2025. The Company continues to anticipate topline results of this trial will be released in <B>October 2025</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is hoped that this trial will enable Travelan<SUP><SUP>&reg;</SUP></SUP>
to be recommended in traveler&rsquo;s diarrhea guidelines thereby increasing its market potential as well as enhancing the long standing
relationship with the US Department of Defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following these results Immuron will request the
end of Phase 2 meeting with the FDA for <B>IMM-124E </B>which all act as a precursor to commencement of a Phase 3 clinical program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on <U>Lumanity</U>&rsquo;s opportunity
assessment prepared for Immuron, the base case yearly revenue in USA for <B>IMM-124E</B> is projected at <B>US$102 million</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IMM-529</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron is progressing with a new Investigational
New Drug (IND) application to the Food and Drug Administration (FDA) to initiate the clinical development of <B>IMM-529</B> for the treatment
of Clostridioides difficile infection (CDI) and prevention of recurrence of CDI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron reported on September 16 that we anticipated
IND submission to the FDA by the end of September 2025. Immuron now anticipates submission in <B>mid-October 2025</B>. Approval of this
IND submission by the FDA is a precursor to commencement of a Phase 2 clinical program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At last year&rsquo;s AGM presentation, we advised
Lumanity&rsquo;s assessment that the IMM-529 market in the US can reach peak revenues of ~<B>US$400 million</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ProIBS product launch</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron reported on September 16 that it anticipated
launch of ProIBS in Q1, calendar 2026. Immuron now anticipates a limited launch in <B>Q4, calendar 2025</B> with a full launch in Q1,
calendar 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>ProIBS</U><SUP><SUP>&reg;</SUP></SUP> is a European certified medical
product for the treatment of symptoms related to Irritable Bowel Syndrome (IBS) such as abdominal pain, bloating and changes in bowel
movement (i.e., diarrhea and/or constipation). Immuron has listed ProIBS<SUP><SUP>&reg;</SUP></SUP> in Australia as a listed complementary medicine. Immuron
is purchasing the product from <U>Calmino</U> and anticipates making a gross margin typical for a consumer health product in Australia.
The IBS treatment market in Australia is estimated to be a part of the broader &ldquo;Digestives &amp; Intestinal Remedies&rdquo; market,
generating a revenue of around <U>A$221 million</U> in 2025, with a projected annual growth rate of 3.28%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pre-clinical Trial Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>On January 5 </B>Immuron reported a research
collaboration with Monash University to develop a new therapeutic against Vancomycin-resistant enterococci (VRE). Immuron has named this
drug candidate <B>IMM-986</B>. VRE antimicrobial resistance (AMR) poses a significant threat to healthcare systems worldwide. AMR can
lead to more severe and harder-to-treat infections in healthcare settings, such as hospitals and nursing homes. These infections often
result in longer hospital stays, higher medical costs, and increased mortality rates. In the U.S., the estimated national cost to treat
these infections exceeds $4.6 billion annually (<U>CDC Antimicrobial Resistance Facts and Stats</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VRE-specific vaccines have been successfully developed
and administered to animals. The VRE colostrum harvested from these immunized subjects has been processed into a freeze-dried powder for
use in this program. Monash has completed the development of analytical assays to characterize the antibody response in IMM-529. Preliminary
analyses have confirmed that IMM-986 exhibits high levels of reactive antibodies targeting vaccine VRE bacterial antigens, as demonstrated
through endpoint ELISA and Western Blot assays. These findings indicate a robust antibody response to VRE. Further characterization of
the specificity and broad-spectrum cross-reactivity of IMM-986-derived antibodies against other enterococcal strains is currently underway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Monash are planning initial pre-clinical studies
to be performed by the <B>end of calendar 2025</B>. Key milestone dates, including the anticipated timing of the initial pre-clinical
study results, will be communicated in due course following the receipt of ethics approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thank you for your ongoing support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Steven Lydeamore</TD><TD STYLE="text-align: justify; width: 60%"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Steven Lydeamore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This release has been authorised by the directors
of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="margin: 0"><B>COMPANY CONTACT:</B> <B></B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B> <B>Steven Lydeamore</B></P>

<P STYLE="margin: 0">Chief Executive Officer</P>

<P STYLE="margin: 0">steve@immuron.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This document may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0P# 2(  A$! Q$!_\0
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MH/Q7F\]8=;@0QL<>?",%?JO?\*V?$_Q+LM*(M]+5+VX*@F3=^[3(XZ=36?\
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MI[9:3FXL8+@@ R1JY [9&:\[T[XG32^(197\%M!:!W#S9.5"@G^@KO\ 2_\
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M*OOJG_H0KC/A!_R%M2_ZX+_Z%7:?$/\ Y$F^_P" ?^A"N+^$'_(4U+_K@O\
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M4H-6TNWOK=@T<R!N.Q[CZ@TL8KTZ<EM;_(,([5*D7O?_ #+E>&?$S_D=Y_\
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98Y&&&D8EG/XFM:BBLY2<G=LTC%15DC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 S$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ
M&>\MK89GN(HA_MN%_G65<^+=%MNMX)#Z1J6_7I6D*52?PQ;^1E.M3I_')+YF
MW17'7/Q"LDR+>SFD/8NP4?IFLBY^(&HR<00P0CZ%C^O'Z5V0R[$2^S;U.&>:
M86'VK^B/2*CFN(+==TTT<:^KL!_.O)+GQ-K%UD27\H![(=G\L5F/-)(Q9W9F
M/4D\UUPRB7VY?<<53.X_8A][/6;GQ7HUMUO%D/I&"WZCBL>Y^(-HF1;6<LA[
M&1@O\LUYWFC-=L,KH1WN_P"O(X*F<8F7PV7R_P SK+GQYJ<N1"D, [$+D_KG
M^58]SKVJ7?\ KKZ<@]@V!^0XK+S37ECC&7=5^IQ79##48?#%'!4Q5>I\<V_F
M3^:_]XT53^WVO_/Q'^=%;Z&&I[Y114=Q/':VTMQ,VV*)"[GT &37PA^BE'6M
M=T_P_9&ZU"<1J>%4<LY] *\YOOC#+YI%AID8C!ZS.22/H,8J=)-/O()?&GBD
M>; [E-/LCR-H)Q\O<G!]NI-00_$'4]1#1VGARR;3@<"*3H1Z9Z?I77"FME&[
M%I:\G8MZ3\7K>:9(M4L#"K'!EA;('_ 3_C7H]I=V]_:QW5K,DT$@RCJ<@BO#
M/$>F:7J-C_;>BPFTVRB&]LF_Y8.>A'^R<8]/I5WX;>(YM(UT:1<LPMKI]FUO
MX).Q'UZ?_JISI*4;Q5F-JVJ9[9117"_%#4[_ $O1K.2PO)K:1IB&:)L$C'2N
M>E3=2:@NIG4FJ<7)]#NJ*YV/6_[+\!P:O=LTSI:(Y+'EW(&,GW)KS_3;;QCX
MZ\W4%U0VMLKE4^=D3/HH7T]36U/#.2<I-)+2YG.NHV25VSV*BO&+CQ7XL\)R
M7.C7TPGG*CR9I/G*@]U/?Z'I5UO"GCLV?]J'6)/M6WS/(\]M_KCTS[5H\'RZ
MRFDGMYF:Q5](Q;:W\CUJBN(^'OBZY\06\]EJ&#>6P!\P#&]3QR/4&LKQGXJU
M>Y\1)X;T!VCER$DD3AF8C. >P ZFLUA9NHZ;Z?=8T>(A[-374],HKR*^T;QK
MX2M?[676#<1QD-,@D9P![ANH^E,MK_Q;\0;R465V+"TA #A'*H#]1R36GU.Z
MYE-<O<S^M6?*XN_8]@HKQ\:OXE\ ZW!;:K=->V,O/+%@RYP2I/((]*ZWXCZG
M=V/A2*ZTZ[EMW>=,21-@E2":AX62G&*::ELRUB$XR;5FMT=G16)X0N9[SPGI
MMQ<RO+-)%EW<Y+')ZUD?$O4+S3?#*3V-U+;2FX5=\38.,'BLHTG*K[/K>QI*
MHE3]IY7.RHK@=2U34(OA/!J"7DRWABC)G#?.26YYKE=(N?&7C&V2RM-0DBM[
M88EN&<KO8G/S$<D^PK:&$<HN3DDD[&4L2DU%)MM7/:**\AUCQ!XF%U:> O#,
MHFU:&(&^U#)(B!YX)Z<$<]>@%4;[P2FALDNK_$;4(=5;YLQEF"GUVYSC\JE8
M:[M??;1OYF[G&,>:;MZGME%>?^%/$>LZ??)HGB25+[SH3/I^IVZ\748Z@C^\
M!SCK7=QW,,ML+F.56A*[@X/&*PG3<'9E71+17D=UXB\2>-];EL- E:ULH\_,
MK;?ESC<S=>?04S4--\:^#(AJ*ZJUW;(1YF'9U'^\K=O>NM8-Z1E)*3Z'*\4M
M6HMI=3U^BL7PMX@C\2:)%?(GER9*2QY^ZXZ_A6U7'*+C)Q>Z.F,E))H****D
MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYYZGWJ&SM4U_Q38Z?:+FTML)D<C&>3_GTIQ3C%RF*<TWRQ\_RL>\UYU\7_\
MD V/_7P?_0:]%KSSXN([Z%9!$9CYY^Z,_P -<F#_ (\3/%?P9#O$7_)'X?\
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MHZ:7J0=&4^<GWAC^&O1ZC&?QY%87^#$****Y#I"BBB@ HHHH **** "BBB@
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M\:;110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +<# 2(  A$! Q$!_\0
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
